No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
CA Stock MarketDetailed Quotes
RVV Revive Therapeutics Ltd
- 0.020
- +0.005+33.33%
15min DelayMarket Closed Jul 12 15:43 ET
7.17MMarket Cap-1000P/E (TTM)
0.020High0.010Low1.23MVolume0.015Open0.015Pre Close19.23KTurnover0.06052wk High0.34%Turnover Ratio358.45MShares0.00552wk Low-0.02EPS TTM7.17MFloat Cap0.960Historical HighLossP/E (Static)358.45MShs Float0.005Historical Low-0.02EPS LYR66.67%Amplitude--Dividend TTM0.74P/B1Lot Size--Div YieldTTM
Intraday
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Express News | Revive Therapeutics Ltd - Additional Phase 3 Clinical Trial Data Analyses May Suggest Bucillamine's Potential for Long Covid.
Express News | Revive Therapeutics Ltd - FDA Has Recommended That Evaluation of Bucillamine for Long Covid Be Submitted as a New Ind Application
Express News | Revive Therapeutics Ltd - Company Is Exploring Use of Bucillamine as a Potential Treatment for Long Covid
Express News | Revive Therapeutics Ltd: Would Be Required to Conduct a Clinical Study for De Novo Submission for Possible Approval
Express News | Revive Therapeutics Ltd: FDA Has Determined That Product Should Follow De Novo Regulatory Pathway
Express News | Revive Therapeutics Ltd - Meeting Date Assigned by FDA Is June 7, 2024
Heat List
CA
Overall
Symbol
Latest Price
%Chg